Ultra-LEAF™ Purified anti-mouse Antibody CCL5 (RANTES), CCL5, W20042A,BioLegend,947004

Host

Rat

Reactivity

Mouse

Application

Neut - Quality tested

Platform ID

BAB647057523

BioLegend

Headquarters

8999 BioLegend Way San Diego, CA 92121 United States

Contact

Tel: 1-858-455-9588
Fax: +49 (4131) 7023913

Email:

Product Specifications
Scientific Background

Specifications

NameUltra-LEAF™ Purified anti-mouse Antibody CCL5 (RANTES), CCL5, W20042A
Cat. No.947004
HostRat
RRIDAB_2910508 (BioLegend Cat. No. 947003)AB_2910508 (BioLegend Cat. No. 947004)
IsotypeRat IgG2a, λ
ReactivityMouse
ApplicationNeut - Quality tested
ClonalityMonoclonal
Clone NumberW20042A
ConcentrationThe antibody is bottled at the concentration indicated on the vial, typically between 2 mg/mL and 3 mg/mL. Older lots may have also been bottled at 1 mg/mL. To obtain lot-specific concentration and expiration, please enter the lot number in ourCertificate of Analysisonline tool.
TargetCCL5
ImmunogenRecombinant mouse CCL5 (RANTES)
PurityThe Ultra-LEAF™ (Low Endotoxin, Azide-Free) antibody was purified by affinity chromatography.
Formulation0.2 µm filtered in phosphate-buffered solution, pH 7.2, containing no preservative.
StorageThe antibody solution should be stored undiluted between 2°C and 8°C. This Ultra-LEAF™ solution contains no preservative; handle under aseptic conditions.
Regulatory StatusResearch Use Only

Scientific Background

CCL5 is a CC chemokine that directs the migration of leukocytes in immune and inflammatory responses. Increased CCL5 expression has been associated with a wide range of inflammatory disorders and pathologies. It has been shown that CCL5 is highly expressed by breast tumor cells at primary tumor sites and is strongly associated with the progression of breast cancer. CCL5 may contribute to tumor progression by recruiting monocytes into tumor sites, and CCL5 can also stimulate the release of MMP, thereby promoting tumor cell migration. Some studies also show that CCL5 has pro-angiogenesis effectsin vivoandin vitro. CCL5 oligomerization and binding to GAGs can induce angiogenic effects through its receptor CCR1 and CCR5. CCL5 is expressed in the early stages of many viral infections. It has been shown that CCL5 is protective against many viruses including influenza, RSV, HCMV, HCV, and HIV. CCL5 can inhibit HIV infection by competing with the virus for CCR5 binding. CCL5 also has been implicated in the development of asthma, artherosclerosis, and fibrosis.

Category Paths

Request a product

Please provide the required information below so that we can quickly source your products.